Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Chopin
Gabriel Ducrocq

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Breast (Edinburgh, Scotland)|May 6, 2017
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, et al.
Breast Cancer Research and Treatment|September 22, 2018
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impactGilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.
Annals of Surgical Oncology|August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary CentersFulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
Cancer Medicine|September 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastasesGilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, et al.
European Journal of Cancer Care|September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes regionDomenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Gynecologic Oncology|April 4, 2020
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG groupAudrey Chevrot, Nicolas Pouget, Anne-Sophie Bats, et al.
Breast Cancer Research and Treatment|February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional studyAlexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer SurvivorsAntonio Di Meglio, Cecile Charles, Elise Martin, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|April 12, 2023
[Treatments for rare ovarian tumors: What's new?]Coriolan Lebreton, Stanislas Quesada, Marta Bini, et al.
Breast (Edinburgh, Scotland)|May 6, 2017
Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB)Gilles Houvenaeghel, Eric Lambaudie, Monique Cohen, et al.
Breast Cancer Research and Treatment|September 22, 2018
Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impactGilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, et al.
Annals of Surgical Oncology|August 17, 2022
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary CentersFulvio Borella, Stefano Cosma, Domenico Ferraioli, et al.
Cancer Medicine|September 21, 2022
The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastasesGilles Houvenaeghel, Alexandre de Nonneville, Nicolas Chopin, et al.
European Journal of Cancer Care|September 7, 2020
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes regionDomenico Ferraioli, Olivia Bally, Pierre Meeus, et al.
Gynecologic Oncology|April 4, 2020
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG groupAudrey Chevrot, Nicolas Pouget, Anne-Sophie Bats, et al.
Breast Cancer Research and Treatment|February 4, 2017
Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional studyAlexandre de Nonneville, Anthony Gonçalves, Christophe Zemmour, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2022
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer SurvivorsAntonio Di Meglio, Cecile Charles, Elise Martin, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancerPaola Bonaventura, Audrey Page, Olivier Tabone, et al.
Pageof 7